"For more than two months, Cypress' Board of Directors undertook a comprehensive evaluation of the companies strategic alternatives,” said Daniel H. Petree, lead independent director of Cypress' Board of Directors. “After thorough and extensive analysis with our financial advisors, Cypress' Board unanimously concluded that this transaction with Royalty Pharma provides significant cash value to our stockholders and is in the best interests of our stockholders, customers and employees."
At a Glance
Central Nervous System
Savella® is an FDA-approved treatment for fibromyalgia, a chronic condition characterized by widespread pain and additional symptoms which may make it difficult to work or to perform everyday activities. People with fibromyalgia have a lower threshold for pain due to central sensitization, which is caused by changes in the central nervous system (brain and spinal cord). These changes include abnormal levels of neurotransmitters, chemicals that are responsible for passing along, and sometimes changing, pain signals. Savella is a type of medication known as a dual reuptake inhibitor (also known as a serotonin-norepinephrine reuptake inhibitor, or SNRI).
Applications In Development: